Evidence map›Paper›PMID 35605529›Full record

Trial reportDrug and alcohol dependence2022

Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone.

Judith I Tsui, Aimee N C Campbell, Martina Pavlicova, Tse-Hwei Choo, Joshua D Lee, Ryan R Cook, Matisyahu Shulman, Edward V Nunes, John Rotrosen

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol dependence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02032433 (CTN-0051), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02032433 phase4completednot on this map

CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment

TypeinterventionalSponsorNYU Langone HealthRan2014 to 2017Enrolled570ConditionsOpioid Use DisorderArmsExtended-Release Naltrexone, Buprenorphine-Naloxone
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Judith I TsuiDepartment of Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA 98195-6420, USA. Electronic address: tsuij@uw.edu.
Aimee N C CampbellDepartment of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA.
Martina PavlicovaDepartment of Biostatistics, Columbia University, 722 West 168th St., New York, NY 10032, USA.
Tse-Hwei ChooDepartment of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA.
Joshua D LeeDepartment of Medicine, New York University, 550 First Avenue, New York, NY 10016, USA.
Ryan R CookDepartment of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.
Matisyahu ShulmanDepartment of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA.
Edward V NunesDepartment of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA.
John RotrosenPsychiatry, New York University, 550 First Avenue, New York, NY 10016, USA.
Columbia University · USNew York University · USOregon Health & Science University · USUniversity of Washington · US

Funding

Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)UG1DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI Mary Akiko Hatch, John M. Roll · 2015 to 2026
$19.8M
NIDA NIH HHS UG1 DA013714
6 · The paper itself

Abstract

backgroundMethamphetamine use is increasing among persons with opioid use disorder (OUD). The study aims were to describe methamphetamine/amphetamine (MA/A) use among patients treated for OUD with buprenorphine/naloxone (BUP-NX) or extended-release naltrexone (XR-NTX), and to explore associations between treatment arm and MA/A use.

methodsSecondary analysis of data from a multi-site, open-label, randomized controlled trial of XR-NTX versus BUP-NX for 24 weeks. The outcome variable was MA/A use defined by either positive urine drug toxicology or self-report. The main predictor was treatment assignment (BUP-NX v. XR-NTX). Longitudinal mixed-effects logistic regression models were fit to model the odds of MA/A use during the study. Additional predictors included study visit and baseline MA/A use.

resultsAmong the sample of 570 participants with OUD, baseline use of MA/A was observed in 105 (18.4%). There was no significant treatment effect over the study period, though BUP-NX subjects, on average, had about half the odds of MA/A use compared to XR-NTX subjects (OR=0.50; p = 0.051). In the same model, baseline MA/A use and study visit were both significantly associated with MA/A use over time.

conclusionIn this sample of treated OUD patients, nearly a fifth of participants had MA/A use at baseline and the frequency of use did not decline over time: in fact, the odds of use slightly increased for each later visit. These secondary analyses found no significant difference in MA/A use between BUP-NX and XR-NTX treatment arms, however, the observation of less MA/A in the buprenorphine arm merits further investigation. CLINICAL

trial registrationClinicalTrials.gov (NCT02032433).

Indexed as

BuprenorphineMethamphetamineOpioid-Related DisordersBuprenorphine, Naloxone Drug CombinationDelayed-Action PreparationsHumansInjections, IntramuscularNaltrexoneNarcotic AntagonistsBuprenorphineBuprenorphine, Naloxone Drug CombinationDelayed-Action PreparationsMethamphetamineNaltrexoneNarcotic AntagonistsAmphetamine useMethamphetamine useOpioid use disorderSubstance use treatment

Identifiers

PMID35605529
PMCPMC10796081
OpenAlexW4224219174

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.